Hong Kong-listed innovative pharmaceutical stocks surged against the trend, with related ETFs seeing funds being "added and withdrawn" during the layout.

Last week, the Hong Kong stock market's innovative drug sector surged against the trend, with several related thematic ETFs rising by as much as 8%. Funds flowed out of the GF CSI Hong Kong Innovative Drug ETF and other similar ones. Additionally, international gold prices have rebounded recently, with COMEX gold futures prices back above $3350 per ounce. Gold stock ETFs rebounded last week, with a general increase of over 6%. Five military-themed ETFs, including the GF CSI Military Industry Leading ETF, received attention from onshore funds last week, with a total net inflow exceeding 20 billion yuan. At the current position, industry experts believe that the A-share market is still in a phase of oscillation and repair. Looking upwards, there are currently no clear catalytic factors driving a rapid rise in the index. Looking downwards, the overall undervaluation of the A-share market provides a high safety margin. With the expectation of the recovery of foreign trade and the economy, there is potential for a continued increase in listed company profits. The market may return to a profit-driven trajectory, highlighting the stability of the Chinese economy and policies. Consumer, cyclical, and self-controllable sectors are expected to attract more market attention.